Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Uncontrolled, Single Center, Phase I Trial to Assess the Safety of VM206RY in Subjects With Expression of Her2 in Breast Cancer

NCT01895491 is registered in ClinicalTrials.gov with Reyon Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT01895491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01895491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Uncontrolled, Single Center, Phase I Trial to Assess the Safety of VM206RY in Subjects With Expression of Her2 in Breast Cancer
Lead sponsor
Reyon Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2011
Completion date
October 31, 2013
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer